Author

David H. Peng

The University of Texas MD Anderson Cancer CenterORCID 0000-0003-0511-1888Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Timothy Paul HeffernaniD· 2 shared Aaron A. Bickert· 1 shared Alondra N. Camacho-Acevedo· 1 shared Amari M. SockwelliD· 1 shared Amrita BaruaiD· 1 shared Andrew J. AguirreiD· 1 shared Anirban MaitraiD· 1 shared Aparna PadhyeiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Timothy Paul HeffernanORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 2, 2026

KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

Jonathan M. DeLiberty, Fan Yi Kong, Qijia Yu…·Joseph Douglas Mancias

This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.

DOI 10.64898/2026.10.01.756025

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 25, 2025

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Amrita Barua, Samrat T. Kundu, Sofia Garza…·Don Lynn Gibbons

This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.

DOI 10.64898/2025.12.22.696060

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 29, 2025

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

Kathleen M. McAndrews, Krishnan K. Mahadevan, Bingrui Li…·Raghu Kalluri

This study investigates how CDK8 remodels the tumor microenvironment to resist KRASG12D inhibition in PDAC, showing that targeting CDK8 can overcome resistance and improve survival.

4 citations

humanspatial transcriptomics

𝕏 PostBluesky